|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
225,410,000 |
Market
Cap: |
170.27(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.4783 - $1.82 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8 |
Insider 3/6 Months : 8.6 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Co.'s clinical-stage product candidates include: Seralutinib, also known as GB002, which is an inhaled small molecule, platelet-derived growth factor receptor colony-stimulating factor 1 receptor and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, which is an oral small molecule for the treatment of inflammatory bowel disease; and GB5121, which an oral small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
232,000 |
232,000 |
1,400,505 |
Total Buy Value |
$0 |
$138,093 |
$138,093 |
$2,465,139 |
Total People Bought |
0 |
2 |
2 |
5 |
Total Buy Transactions |
0 |
2 |
2 |
12 |
Total Shares Sold |
44,068 |
44,068 |
45,882 |
92,014 |
Total Sell Value |
$52,319 |
$52,319 |
$54,659 |
$336,499 |
Total People Sold |
5 |
5 |
5 |
6 |
Total Sell Transactions |
5 |
5 |
6 |
14 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Carter Laura |
Chief Scientific Officer |
|
2022-07-01 |
4 |
S |
$8.25 |
$72,648 |
D/D |
(8,808) |
80,234 |
|
-24% |
|
Aranda Richard |
Chief Medical Officer |
|
2022-06-22 |
4 |
S |
$6.88 |
$12,233 |
D/D |
(1,778) |
209,897 |
|
-49% |
|
Carter Laura |
Chief Scientific Officer |
|
2022-05-04 |
4 |
S |
$7.20 |
$9,086 |
D/D |
(1,262) |
89,042 |
|
-93% |
|
Giraudo Bryan |
COO/CFO |
|
2022-03-23 |
4 |
S |
$8.92 |
$95,587 |
D/D |
(10,722) |
99,167 |
|
-34% |
|
Hasnain Faheem |
President & CEO |
|
2022-03-23 |
4 |
S |
$8.92 |
$169,697 |
D/D |
(19,035) |
143,465 |
|
-34% |
|
Christian Waage |
EVP, Tech Ops and Admin |
|
2022-03-23 |
4 |
S |
$8.92 |
$95,587 |
D/D |
(10,722) |
579,008 |
|
-34% |
|
Aranda Richard |
Chief Medical Officer |
|
2022-03-16 |
4 |
S |
$8.28 |
$51,976 |
D/D |
(6,278) |
211,675 |
|
-35% |
|
Peterson Caryn |
EVP, Regulatory Affairs |
|
2022-03-16 |
4 |
S |
$8.28 |
$51,978 |
D/D |
(6,279) |
66,172 |
|
-35% |
|
Carter Laura |
Chief Scientific Officer |
|
2022-03-16 |
4 |
S |
$8.28 |
$41,407 |
D/D |
(5,002) |
90,304 |
|
-35% |
|
Carter Laura |
Chief Scientific Officer |
|
2021-10-25 |
4 |
S |
$12.25 |
$29,118 |
D/D |
(2,377) |
95,306 |
|
27% |
|
Peterson Caryn |
EVP, Regulatory Affairs |
|
2021-10-25 |
4 |
S |
$12.25 |
$29,118 |
D/D |
(2,377) |
72,451 |
|
27% |
|
Aranda Richard |
Chief Medical Officer |
|
2021-10-25 |
4 |
S |
$12.25 |
$29,118 |
D/D |
(2,377) |
217,432 |
|
27% |
|
Carter Laura |
Chief Scientific Officer |
|
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
97,683 |
|
- |
|
Aranda Richard |
Chief Medical Officer |
|
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
219,809 |
|
- |
|
Carter Laura |
Chief Scientific Officer |
|
2021-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,820 |
72,683 |
|
- |
|
Peterson Caryn |
EVP, Regulatory AffairsOfficer |
|
2021-04-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,008 |
|
13% |
|
Peterson Caryn |
EVP, Regulatory Affairs |
|
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,820 |
74,828 |
|
- |
|
Salter-Cid Luisa |
Chief Scientific Officer |
|
2021-03-23 |
4 |
S |
$9.48 |
$52,052 |
D/D |
(5,491) |
206,065 |
|
16% |
|
Christian Waage |
EVP & General Counsel |
|
2021-03-23 |
4 |
S |
$9.48 |
$52,051 |
D/D |
(5,490) |
588,199 |
|
16% |
|
Giraudo Bryan |
Chief Financial Officer |
|
2021-03-23 |
4 |
S |
$9.48 |
$52,046 |
D/D |
(5,490) |
109,889 |
|
16% |
|
Christian Waage |
EVP & General Counsel |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
593,689 |
|
- |
|
Giraudo Bryan |
Chief Financial Officer |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
115,379 |
|
- |
|
Salter-Cid Luisa |
Chief Scientific Officer |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
211,556 |
|
- |
|
Hasnain Faheem |
President & CEO |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
162,500 |
162,500 |
|
- |
|
Christian Waage |
EVP & General Counsel |
|
2020-10-14 |
4 |
B |
$9.53 |
$23,818 |
I/I |
2,500 |
6,954 |
1.99 |
11% |
|
27 Records found
|
|
Page 1 of 2 |
|
|